医学
放射性核素治疗
前列腺癌
心脏毒性
内科学
肌钙蛋白
神经内分泌肿瘤
肌钙蛋白I
癌症
泌尿科
心脏病学
化疗
心肌梗塞
作者
Esmail Jafari,Abdullatif Amini,Hojjat Ahmadzadehfar,Dara Bagheri,Majid Assadi
出处
期刊:Nuklearmedizin-nuclear Medicine
[Schattauer Verlag]
日期:2021-01-18
卷期号:60 (02): 99-105
被引量:13
摘要
BACKGROUND: Lu-PSMA by evaluation of serum troponin I and cardiac profile change during a follow-up time. MATERIALS AND METHODS: Patients with prostate cancer and neuroendocrine tumours (NETs) referred for PRRT and RLT, respectively, were enrolled in this study. The cardiac profiles of the patients were evaluated by a cardiologist and a cardiac history was obtained from all patients. Also, troponin I was measured before and 48 hours after treatment. RESULTS: In this retrospective study for assessment of RLT associated cardiotoxicity, 24 patients were evaluated with a median age of 64 years (27-99 years) including 13 NET patients and 11 prostate cancer patients. Patients were followed up for 4 to 31 months which no cardiovascular problem was observed. In evaluation of troponin I, 39 RNT cycles were evaluated. In all patients, the value of troponin I was in normal range. In all patients, the median values of serum troponin I before and after treatment were 0.2 ± 0.02 (range: 0.00-0.42) and 0.28 ± 0.02 (range: 0.00-0.46) ng/ml, respectively (p > 0.05). In the prostate cancer patients, the median values of serum troponin I before and after treatment were 0.26 ± 0.04 (0.04-0.42) and 0.30 ± 0.04 (0.00-0.41) ng/ml, respectively (p > 0.05). In the NET patients, the median values of serum troponin I before and after treatment were 0.18 ± 0.03 (0.00-0.42) and 0.17 ± 0.03 (0.00-0.46) ng/ml, respectively (p > 0.05). CONCLUSION: Lu-PSMA as emerging therapeutic modalities have no significant cardiotoxicity. However, further well-designed studies are recommended.
科研通智能强力驱动
Strongly Powered by AbleSci AI